- AREV NanoTech (AREV) appoints Dr. Roscoe Moore to the Scientific Advisory Board for AREV Nanotec Brands Inc
- Dr. Moore served on the Board of Directors for the Africa Center for Health and Human Security at George Washington University from 2006 to 2009
- The IHV is the first research institute in the U.S. to link basic science, population studies and clinical trials to develop new vaccines and treatments
- AREV has issued 250,000 stock options to Directors, Officers and Consultants of AREV at C$0.31 for a period of five years from the issue date
- AREV NanoTech (AREV) is up 11.48 per cent and is trading at C$0.34 at close
AREV (AREV) has appointed Dr. Roscoe Moore DVM, MPH, Ph.D., Former Assistant United States Surgeon General, to the Scientific Advisory Board for AREV Nanotec Brands Inc.
Dr. Moore will provide strategic planning for AREV drug discovery planning as a Senior Scientific Advisor.
Dr. Moore is a member of the Board of Advisors and the Board of Directors of the Global Virus Network at the Institute of Human Virology (IHV), University of Maryland Medical Center.
According to the National Science Foundation, UMB’s budget for research and development in 2019 was $1.1 billion, ranking it 14 overall in the nation and eight among all public institutions.
The IHV currently retains more than 300 employees including more than 80 faculty members whose research efforts are focused on the area of chronic human viral infection and disease and contributing to research on pandemic pathogens, ranging from COVID-19 to HIV.
Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service, entering with the U.S. National Institutes of Health and rising to Assistant United States Surgeon General within the Immediate Office of the Secretary, HHS. Dr. Moore served as an Epidemic Intelligence Service Officer with the U.S. Centers for Disease Control and Prevention (“CDC”).
He has also served as an Affiliate Associate Professor of Environmental Health for the University of Washington, Seattle, from 1994 to 2003 and as an Adjunct Professor of Epidemiology for the Medical University of Southern Africa, Pretoria, South Africa, from 1999 to 2002.
He served on the Board of Directors for the Africa Center for Health and Human Security, at George Washington University from 2006 to 2009.
AREV Nanotech’s CEO, Mike Withrow, commented, “We’re very excited to welcome Dr. Moore to the AREV Nanotec Scientific Advisory Board. Dr. Moore’s introduction to AREV Nanotech represents the emerging discovery opportunities being presented to the company now, as we pursue a range of pre-clinical investigations intended to identify antiviral phytomedicinal chemistries.”
Dr. Moore commented, “AREV Nanotech is developing a range of integrated extraction technologies that will help mature phytomedicinal discovery and advance promising therapies from bench to bedside.”
AREV has issued 250,000 stock options to Directors, Officers and Consultants of AREV at C$0.31 for a period of five years from the issue date.
AREV NanoTech (AREV) is up 11.48 per cent and is trading at C$0.34 at close.
